Abstract:Introduction Metabolic syndrome and cardiovascular diseases are a very important cause of morbidity and mortality among patients with schizophrenia who live an average of 10-20 years less than the general population. Second generation antipsychotics are associated with obesity and other components of the metabolic syndrome. Objectives The aim of this paper was to provide complete insight into the existing recent evidence for metabolic risks associated with the use of new antipsychotics, and establish recommendations for monitoring metabolic syndrome and other risks, as well as current options for treatment and prevention of metabolic syndrome. Methods This review article is based on a literature search. We identified relevant publications and articles by searching the PUBMED database from 1999 to the present day according to the given parameters. The search criteria were the keywords "metabolic syndrome" combined with "schizophrenia" and "new antipsychotics". Results All researches has convincingly shown that patients with schizophrenia tend to be overweight and have a three to four times higher risk of developing diabetes than the general population. There are also more and more evidence in recent literature about the impact of new antipsychotics on the frequency of metabolic syndrome in patients with schizophrenia. The World Health Organization (WHO) defines metabolic syndrome as an elevated insulin level or a fasting glucose concentration of 5.6-6.0 mmol/l in combination with two or more of the following parameters: abdominal or central obesity and dyslipidemia and/or arterial hypertension. The research results systematically showed a 1.5 to 3 times higher frequency of metabolic syndrome in people suffering from schizophrenia compared to the general population. Therefore, regular control of all components of the metabolic syndrome is necessary, from waist circumference, which is the easiest to measure, to all others that can be carried out and done in the general practice doctor's office. Conclusions Metabolic changes in patients with shizophrenia who receive new antipsychotics in addition to their unfavorable lifestyle (improper diet, lack of physical activity, smoking) can lead to the development of metabolic syndrome and increase the risk for diabetes and cardiovascular diseases. It is therefore necessary to establish protocols for monitoring these risks and preventing comorbidities. Disclosure of Interest None Declared

Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder

Prevalence and Correlation of Metabolic Syndrome in Patients with Bipolar Disorder in NGHA, Riyadh

A Systematic Review and Meta-Analysis of Metabolic Syndrome Prevalence in Chinese Inpatients with Bipolar Disorder

Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders

Prevalence of metabolic syndrome and its related factors in schizophrenic inpatients

Metabolic Syndrome and Its Associated Factors Among Patients With Schizophrenia Treated With Second-Generation Antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia

Prevalence of metabolic syndrome and its associated factors in first‐treatment drug‐naïve schizophrenia patients: A large‐scale cross‐sectional study

Metabolic syndrome in psychiatric patients with schizophrenia

Subclinical hypothyroidism and metabolic syndrome in psychiatric patients: A systematic literature review and meta-analysis

Incidence and predictors of metabolic syndrome onset in individuals with bipolar disorders: A longitudinal study from the FACE‐BD cohort

Metabolic syndrome in patients with obsessive-compulsive disorder

Gender Differences in Prevalence and Associated Factors of Metabolic Syndrome in First-Treatment and Drug-Naïve Schizophrenia Patients.

Prevalence of Metabolic Syndrome and Its Related Factorsin Schizophrenic Inpatients

Lipid and Glucose Profile across Different Mental Disorders First

Investigation of metabolic syndrome in inpatients with bipolar disorder

Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder

Factors Associated with the Prevalence of Psychiatric Disorders Among Saudi Adults in the Eastern Region and Their Health Implications

Comorbid Metabolic Syndrome and Its Risk Factors of Patients with Bipolar Disorder

Causes and risk factors for common mental illnesses: the beliefs of paediatric hospital staff in the United Arab Emirates

Sociodemographic and diagnostic trends of users accessing psychiatry outpatient clinic in Dubai from 2019 to 2023: a cross-sectional retrospective study

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome